Otsuka (4578) M&A announcement summary

Deal rationale and strategic fit

• Acquisition strengthens the portfolio with a late-stage, next-generation psychiatric treatment asset, TSND-201, targeting PTSD and treatment-resistant depression, and aims for a paradigm shift in psychiatric care.

• Expands options in CNS and psychiatry, leveraging over 25 years of experience and a broad U.S. platform.

• Aligns with strategy to invest current revenues into innovative late-stage products for future growth and supports sustained growth in psychiatric and neurological areas.

• Addresses significant unmet need in PTSD, where only two SSRIs have been approved in 22 years and many patients are treatment-resistant.

• Strengthens the business platform in CNS, particularly PTSD, and complements ongoing investments in the field.

Financial terms and conditions

• $700 million upfront payment for 100% equity acquisition via subsidiary, plus up to $525 million in conditional milestone payments tied to product sales at peak.

Synergies and expected cost savings

• Leverages established psychiatric business and commercial development platforms, utilizing expertise from over 25 years in global psychiatry and US market experience since 2002.

• Utilizes existing sales force and broad psychiatric specialist network for product delivery.